Upfront transplantation for poor-risk aggressive non-Hodgkin lymphoma and Hodgkin's disease: Who benefits? Journal Article
| Authors: | Kewalramani, T.; Moskowitz, C. H. |
| Article Title: | Upfront transplantation for poor-risk aggressive non-Hodgkin lymphoma and Hodgkin's disease: Who benefits? |
| Abstract: | High-dose therapy with autologous stem-cell transplantation is the standard treatment for patients with relapsed or primary refractory Hodgkin's disease or non-Hodgkin lymphoma. The efficacy of the treatment in this setting has prompted extensive investigation of its role in upfront therapy for patients with a poor prognosis. Although the preliminary data appear promising, definitive results are still lacking, and upfront transplantation remains investigational. Newer regimens for the treatment of advanced-stage Hodgkin's disease appear to confer cure rates of approximately 85% to 90%. Thus, only a small minority of patients may potentially benefit from more aggressive therapy such as upfront transplantation. A reliable method of identifying these patients is yet to be determined. Upfront transplantation should be evaluated in these patients once they are identified. |
| Keywords: | disease course; review; antineoplastic agent; antineoplastic combined chemotherapy protocols; hematopoietic stem cell transplantation; hodgkin disease; nonhodgkin lymphoma; lymphoma, non-hodgkin; disease progression; transplantation, autologous; autotransplantation; humans; prognosis; human |
| Journal Title: | Current Oncology Reports |
| Volume: | 3 |
| Issue: | 3 |
| ISSN: | 1523-3790 |
| Publisher: | Springer |
| Date Published: | 2001-06-01 |
| Start Page: | 271 |
| End Page: | 278 |
| Language: | English |
| PUBMED: | 11296139 |
| PROVIDER: | scopus |
| DOI: | 10.1007/s11912-001-0061-0 |
| DOI/URL: | |
| Notes: | Export Date: 21 May 2015 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
-
407Moskowitz -
63Kewalramani
Related MSK Work